T

T Man Pharmaceutical PCL
SET:TMAN

Watchlist Manager
T Man Pharmaceutical PCL
SET:TMAN
Watchlist
Price: 10.9 THB Market Closed
Market Cap: 4.4B THB
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+30%
Revenue
Forecast
+13%
Operating Income
Forecast
+29%
Net Income
Forecast
-1%

Wall Street
Price Targets

TMAN Price Targets Summary
T Man Pharmaceutical PCL

Wall Street analysts forecast TMAN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TMAN is 19.79 THB with a low forecast of 19.59 THB and a high forecast of 20.37 THB.

TMAN Lowest Forecast
Wall Street Target
19.59 THB
80% Upside
TMAN Average Forecast
Wall Street Target
19.79 THB
82% Upside
TMAN Highest Forecast
Wall Street Target
20.37 THB
87% Upside
Lowest
Price Target
19.59 THB
80% Upside
Average
Price Target
19.79 THB
82% Upside
Highest
Price Target
20.37 THB
87% Upside
T Man Pharmaceutical PCL Competitors:
Price Targets
PNV
Polynovo Ltd
87% Upside
ERIS
Eris Lifesciences Ltd
4% Upside
U
3933
United Laboratories International Holdings Ltd
17% Upside
S
688506
Sichuan Biokin Pharmaceutical Co Ltd
12% Upside
PNV
Polynovo Ltd
87% Upside
ERIS
Eris Lifesciences Ltd
4% Upside
U
3933
United Laboratories International Holdings Ltd
17% Upside
S
688506
Sichuan Biokin Pharmaceutical Co Ltd
12% Upside
NOVN
Novartis AG
13% Upside

Revenue
Forecast

Revenue Estimate
T Man Pharmaceutical PCL

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's revenue is 12%. The projected CAGR for the next 2 years is 14%.

12%
Past Growth
14%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
T Man Pharmaceutical PCL

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's operating income is 14%. The projected CAGR for the next 2 years is 13%.

14%
Past Growth
13%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
T Man Pharmaceutical PCL

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's net income is 5%. The projected CAGR for the next 3 years is 11%.

5%
Past Growth
11%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
TMAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
TMAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TMAN stock valuation using valuation multiples.
Wall Street Estimates
TMAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TMAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TMAN's stock price target?
Price Target
19.79 THB

According to Wall Street analysts, the average 1-year price target for TMAN is 19.79 THB with a low forecast of 19.59 THB and a high forecast of 20.37 THB.

What is T Man Pharmaceutical PCL's Revenue forecast?
Projected CAGR
14%

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's revenue is 12%. The projected CAGR for the next 2 years is 14%.

What is T Man Pharmaceutical PCL's Operating Income forecast?
Projected CAGR
13%

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's operating income is 14%. The projected CAGR for the next 2 years is 13%.

What is T Man Pharmaceutical PCL's Net Income forecast?
Projected CAGR
11%

For the last 1 year the compound annual growth rate for T Man Pharmaceutical PCL's net income is 5%. The projected CAGR for the next 3 years is 11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.